In general, these studies indicated that ERK1/2 takes part in the regulation of several pathways (p53 pathway and death receptor pathway, etc.), and inhibition of ERK1/2 is clearly beneficial for the promotion of apoptosis and tumor therapy. The gene discussed is MAPK3; the disease is neoplasm.